Regulation of protein kinase C by the anti-Parkinson drug, MAO-B inhibitor, rasagiline and its derivatives, in vivo

Journal of Neurochemistry

Volumn 89, Issue 5, 2004, Pages 1119-1125

  Bar Am, Orit ^a   Yogev Falach, Merav ^a   Amit, Tamar ^a   Sagi, Yotam ^a   Youdim, Moussa B H ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Amyloid precursor protein; Myristoylated alanine rich C kinase substrate; Protein kinase C; Rasagiline

Indexed keywords

AMYLOID PRECURSOR PROTEIN; CHOLINESTERASE INHIBITOR; LADOSTIGIL; MARCKS PROTEIN; MONOAMINE OXIDASE B INHIBITOR; PROTEIN KINASE C; RASAGILINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL STRAIN; CONTROLLED STUDY; HIPPOCAMPUS; LEARNING; MALE; MOUSE; MYRISTYLATION; NERVE CELL PLASTICITY; NEUROBLASTOMA CELL; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; WESTERN BLOTTING;

AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANTIPARKINSON AGENTS; CARBAMATES; GLUCOSIDASES; HIPPOCAMPUS; INDANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MONOAMINE OXIDASE INHIBITORS; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEIN KINASE C; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTORS, CELL SURFACE;

ANIMALIA; GYMNOMYZA SAMOENSIS;

EID: 2642529309     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2004.02425.x     Document Type: Article

References (55)

1. Aderem A. (1992) The MARCKS brothers: a family of protein kinase C substrates. Cell 71, 713-716.
2. Akao Y., Maruyama W., Yi H., Shamoto-Nagai M., Youdim M. B. H. and Naoi M. (2002a) An anti-Parkinson's disease drug, N-propargyl-1 (R)-aminoindan (rasagiline), enhances expression of antiapoptotic Bcl-2 in human dopaminergic SH-SY5Y cells. Neurosci. Lett. 326, 105-108.
3. Akao Y., Maruyama W., Shimizu S., Yi H., Nakagawa Y., Shamoto-Nagai M., Youdim M. B. H., Tsujimoto Y. and Naoi M. (2002b) Mitochondrial permeability transition mediates apoptosis induced by N-methyl (R) salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and Rasagiline, N-Propargyl-1 (R)-aminoindan. J. Neurochem. 82, 913-923.
4. Battaini F., Pascale A., Paoletti R. and Govoni S. (1997) The role of anchoring protein RACK1 in PKC activation in the ageing rat brain. Trends Neurosci. 20, 410-415.
5. Battaini F., Pascale A., Lucchi L., Pasinetti G. M. and Govoni S. (1999) Protein kinase C anchoring deficit in postmortem brains of Alzheimer's disease patients. Exp. Neurol. 159, 559-564.
6. Benussi L., Govoni S., Gasparini L., Binetti G., Trabucchi M., Bianchetti A. and Racchi M. (1998) Specific role for protein kinase C alpha in the constitutive and regulated secretion of amyloid precursor protein in human skin fibroblasts. Neurosci. Lett. 240, 97-101.
7. Blackshear P. J. (1993) The MARCKS family of cellular protein kinase C substrates. J. Biol. Chem. 268, 1501-1504.
8. Buxbaum J. D., Gandy S. E., Cicchetti P., Ehrlich M. E., Czernik A. J., Fracasso R. P., Ramabhadran T. V., Unterbeck A. J. and Greengard P. (1990) Processing of Alzheimer beta/A4 amyloid precursor protein: modulation by agents that regulate protein phosphorylation. Proc. Natl Acad. Sci. USA 87, 6003-6006.
9. Caputi A., Barindelli S., Pastorino L., Cimino M., Buxbaum J. D., Cattabeni F. and Di Luca M. (1997) Increased secretion of the amino-terminal fragment of amyloid precursor protein in brains of rats with a constitutive up-regulation of protein kinase C. J. Neurochem. 68, 2523-2529.
10. Finberg J. P., Takeshima T., Johnston J. M. and Commissiong J. W. (1998) Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor. Neuroreport 9, 703-707.
11. Gasparini L., Racchi M., Binetti G. et al. (1998) Peripheral markers in testing pathophysiological hypotheses and diagnosing Alzheimer's disease. FASEB J. 12, 17-34.
12. Hama T., Huang K. P. and Guroff G. (1986) Protein kinase C as a component of a nerve growth factor-sensitive phosphorylation system in PC12 cells. Proc. Ann. NY Acad. Sci. Natl Acad. Sci. USA 83, 2353-2357.
13. Heemskerk F. M., Chen H. C. and Huang F. L. (1993) Protein kinase C phosphorylates Ser152, Ser156 and Ser163 but not Ser160 of MARCKS in rat brain. Biochem. Biophys. Res. Commun. 190, 236-241.
14. Huang W., Chen Y., Shohami E. and Weinstock M. (1999) Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse. Eur. J. Pharmacol. 366, 127-135.
15. Jin L. W. and Saitoh T. (1995) Changes in protein kinases in brain aging and Alzheimer's disease. Implications for drug therapy. Drugs Aging 6, 136-149.
16. Kinouchi T., Sorimachi H., Maruyama K., Mizuno K., Ohno S., Ishiura S. and Suzuki K. (1995) Conventional protein kinase C (PKC)-alpha and novel PKC epsilon, but not-delta, increase the secretion of an N-terminal fragment of Alzheimer's disease amyloid precursor protein from PKC cDNA transfected 3Y1 fibroblasts. FEBS Lett. 364, 203-206.
17. Kribben A., Wieder E. D., Li X., van Putten V., Granot Y., Schrier R. W. and Nemenoff R. A. (1993) AVP-induced activation of MAP kinase in vascular smooth muscle cells is mediated through protein kinase C. Am. J. Physiol. 265, C939-C945.
18. Lin L., Georgievska B., Mattsson A. and Isacson O. (1999) Cognitive changes and modified processing of amyloid precursor protein in the cortical and hippocampal system after cholinergic synapse loss and muscarinic receptor activation. Proc. Natl Acad. Sci. USA 96, 12108-12113.
19. Maher P. (2001) How protein kinase C activation protects nerve cells from oxidative stress-induced cell death. J. Neurosci. 21, 2929-2938.
20. Maruyama W., Youdim M. B. H. and Naoi M. (2000a) Antiapoptotic function of N-propargylamine-1(R)- and (S)-aminoindan, Rasagiline and TV1022. Ann. NY Acad. Sci. 939, 320-329.
21. Maruyama W., Akao Y., Youdim M. B. H. and Naoi M. (2000b) Neurotoxins induce apoptosis in dopamine neurons: protection by N- propargylamine-1(R)- and (S)-aminoindan, rasagiline and TV1022. J. Neural Transm. Suppl. 60, 171-186.
22. Maruyama W., Boulton A. A., Davis B. A., Dostert P. and Naoi M. (2001a) Enantio-specific induction of apoptosis by an endogenous neurotoxin, N-methyl(R)salsolinol, in dopaminergic SH-SY5Y cells: suppression of apoptosis by N-(2-heptyl)-N-methylpropargylamine. J. Neural Transm. 108, 11-24.
23. Maruyama W., Akao Y., Youdim M. B. H., Boulton A. A., Davis B. A. and Naoi M. (2001b) Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3 phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol. J. Neurochem. 78, 727-735.
24. Masliah E., Cole G. M., Hansen L. A., Mallory M., Albright T., Terry R. D. and Saitoh T. (1991) Protein kinase C alteration is an early biochemical marker in Alzheimer's disease. J. Neurosci. 11, 2759-2767.
25. Matsushima H., Shimohama S., Chachin M., Taniguchi T. and Kimura J. (1996) Ca2+-dependent and Ca2+-independent protein kinase C changes in the brain of patients with Alzheimer's disease. J. Neurochem. 67, 317-323.
26. McNamara R. K. and Lenox R. H. (1998) Distribution of the protein kinase C substrates MARCKS and MRP in the postnatal developing rat brain. J. Neurol. 397, 337-356.
27. McNamara R. K., Stumpo D. J., Morel L. M., Lewis M. H., Wakeland E. K., Blackshear P. J. and Lenox R. H. (1998) Effect of reduced myristoylated alanine-rich C kinase substrate expression on hippocampal mossy fiber development and spatial learning in mutant mice: transgenic rescue and interactions with gene background. Proc. Ann. NY Acad. Sci. Natl Acad. Sci. USA 95, 14517-14522.
28. Mills J. and Reiner P. B. (1999) Regulation of amyloid precursor protein cleavage. J. Neurochem. 72, 443-460.
29. Mochly-Rosen D. (1995) Localization of protein kinases by anchoring proteins: a theme in signal transduction. Science 268, 247-251.
30. Montz H. P., Davis G. E., Skaper S. D., Manthorpe M. and Varon S. (1985) Tumor-promoting phorbol diester mimics two distinct neuronotrophic factors. Brain Res. 355, 150-154.
31. Naoi M. and Maruyama W. (2001) Future of neuroprotection in Parkinson's disease. Park. Relat. Disord. 8, 139-145.
32. Nishizuka Y. (1988) The molecular heterogeneity of protein kinase C and its implications for cellular regulation. Nature 334, 661-665.
33. Nitsch R. M., Slack B. E., Wurtman R. J. and Growdon J. H. (1992) Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 258, 304-307.
34. Parkinson Study Group (2002) A controlled trial of rasagiline in early parkinson disease. Arch. Neurol. 59, 1937-1993.
35. Ramsden J. J. (2000) MARCKS: a case of molecular exaptation? Int. J. Biochem. 32, 475-479.
36. Rossner S., Ueberham U., Yu J., Kirazov L., Schliebs R., Perez-Polo J. R. and Bigl V. (1997) In vivo regulation of amyloid precursor protein secretion in rat neocortex by cholinergic activity. Eur. J. Neurosci. 9, 2125-2134.
37. Roth G. S., Joseph J. A. and Mason R. P. (1995) Membrane alterations as causes of impaired signal transduction in Alzheimer's disease and aging. Trends Neurosci. 18, 203-206.
38. Ruvolo P. P., Deng X., Carr B. K. and May W. S. (1998) A functional role for mitochondrial protein kinase Calpha in Bcl2 phosphorylation and suppression of apoptosis. J. Biol. Chem. 273, 25436-25442.
39. Sagi Y., Weinreb O., Weinstock M. and Youdim M. B. H. (2001) Neuroprotective and neurorescue properties of rasagiline and TV3326 in MPTP model of Parkinson's disease. Neural Plas. 8, 197-198.
40. Sagi Y., Weinstock M. and Youdim M. B. H. (2003) Attenuation of MPTP-induced dopaminergic neurotoxicity by TV3326, a cholinesterase-monoamine oxidase inhibitor. J. Neurochem. 2, 290-297.
41. Saitoh T., Horsburgh K. and Masliah E. (1993) Hyperactivation of signal transduction systems in Alzheimer's disease. Ann. NY Acad. Sci. 695, 34-41.
42. Shimohama S., Narita M., Matsushima H., Kimura J., Kameyama M., Hagiwara M., Hidaka H. and Taniguchi T. (1993) Assessment of protein kinase C isozymes by two-site enzyme immunoassay in human brains and changes in Alzheimer's disease. Neurology 43, 1407-1413.
43. Slack B. E., Nitsch R. M., Livneh E., Kunz G. M. Jr, Breu J., Eldar H. and Wurtman R. J. (1993) Regulation by phorbol esters of amyloid precursor protein release from Swiss 3T3 fibroblasts overexpressing protein kinase C alpha. J. Biol. Chem. 268, 21097-21101.
44. Tsujimoto Y. and Shimizu S. (2000) Bcl-2 family: life-or-death switch. FEBS Lett. 466, 6-10.
45. Vianna M. R., Barros D. M., Silva T., Choi H., Madche C., Rodrigues C., Medina J. H. and Izquierdo I. (2000) Pharmacological demonstration of the differential involvement of protein kinase C isoforms in short- and long-term memory formation and retrieval of one-trial avoidance in rats. Psychopharmacology (Berl.) 150, 77-84.
46. Wang H. Y., Pisano M. R. and Friedman E. (1994) Attenuated protein kinase C activity and translocation in Alzheimer's disease brain. Neurobiol. Aging 15, 293-298.
47. Weinstock M., Bejar C., Wang R. H., Poltyrev T., Gross A., Finberg J. and Youdim M. B. H. (2000) TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer's disease. J. Neural Transm. 60 (Suppl.), S157-S170.
48. Weinstock M., Kirschbaum-Slager N., Lazarovici P., Bejar C., Youdim M. B. H. and Shoham S. (2001) Neuroprotective effects of novel cholinesterase inhibitors derived from rasagiline as potential anti-Alzheimer drugs. Ann. NY Acad. Sci. 939, 148-161.
49. Yeon S. W., Jung M. W., Ha M. J., Kim S. U., Huh K., Savage M. J., Masliah E. and Mook-Jung I. (2001) Blockade of PKC epsilon activation attenuates phorbol ester-induced increase of alpha-secretase-derived secreted form of amyloid precursor protein. Biochem. Biophys. Res. Commun. 280, 782-787.
50. Yogev-Falach M., Amit T., Bar-Am O., Sagi Y., Weinstock M. and Youdim M. B. H. (2002) The involvement of mitogen-activated protein (MAP) kinase in the regulation of amyloid precursor protein processing by novel cholinesterase inhibitors derived from rasagiline. FASEB J. 16, 1674-1676.
51. Yogev-Falach M., Amit T., Bar A. M. O. and Youdim M. B. H. (2003) The importance of propargylamine moiety of anti-Parkinson drug rasagiline and its derivatives in MAP kinase dependent APP processing activity. FASEB J. 17, 2325-2327.
52. Youdim M. B. H. and Weinstock M. (2002) Molecular basis of neuroprotective activities of rasagiline and the anti alzheimer drug, TV3326, [(N-Propargyl-(3R)Aminoindan-5-YL)-ethyl methyl Carbamate]. Cell. Mol. Neurobiol. 21, 555-573.
53. Youdim M. B. H., Gross A. and Finberg J. P. M. (2001a) Rasagiline [N-Propargyl-1R(+)-aminoindant], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J. Pharmacol. 132, 500-506.
54. Youdim M. B. H., Wadia A., Tatton N. A. and Weinstock M. (2001b) The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo. Ann. NY Acad. Sci. 939, 450-458.
55. Youdim M. B. H., Amit T., Yogev-Falach M., Bar-Am O., Maruyama W. and Naoi M. (2003) The essentiallity of Bcl-2, PKC and proteasome-ubiquitin complex activations in the neuroprotecitve-antiapoptotic action of the anti-parkinson drug, rasagiline. Biochem. Pharmacol. 66, 1635-1641.